Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 12/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269257 | 0.87 | TDP1 (0.38) | ERN1TDP1CYP2A6TYMSTSHR | |
| SCHEMBL6820167 | 0.81 | TDP1 (0.44) | ERN1TDP1CYP2A6TYMSALOX15 | |
| SCHEMBL3268022 | 0.79 | ERN1 (0.47) | ERN1CYP2A6TYMS | |
| SCHEMBL9446315 | 0.79 | ERN1 (0.65) | ERN1 | |
| SCHEMBL3268752 | 0.79 | ERN1 (0.46) | ERN1TDP1CYP2A6TYMSALOX15 | |
| SCHEMBL30856023 | 0.75 | TDP1 (0.50) | ERN1TDP1CYP2A6TYMSF11 | |
| SCHEMBL10488182 | 0.75 | CYP2A6 (0.45) | ERN1TDP1CYP2A6 | |
| SCHEMBL8153548 | 0.75 | ERN1 (0.45) | ERN1CYP2A6 | |
| SCHEMBL2786544 | 0.73 | ERN1 (0.60) | ERN1TDP1CYP2A6TSHR | |
| SCHEMBL3268893 | 0.73 | ERN1 (0.41) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-03-15 | — | — | US | disclosed |
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| CN-101300244-A | Novel cercosporamide derivative | DAIICHI SANKYO CO LTD (JP) | 2008-11-05 | — | — | CN | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | ERN1 337/4885TDP1 4587/4885CYP2A6 572/4885 |
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, PER2 | ERN1 2978/4885TDP1 4181/4885CYP2A6 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.